HPTN 083: HIV Infections in the Yr 1 Unblinded Period in MSM and TGW Receiving Injectable CAB for HIV PrEP

Washington, DC - October 19-23, 2022; Glasgow, Scotland and virtual - October 23-26, 2022
Efficacy advantage of long-acting CAB over FTC/TDF for HIV PrEP persisted 1 year after unblinding, with 3 new cases of INSTI mutations observed.
Format: Microsoft PowerPoint (.ppt)
File Size: 135 KB
Released: October 27, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Kenric Ware discusses how technology and social media can impact PrEP adherence and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 23, 2023

Dr Kenric Ware discusses considerations for ongoing PrEP candidacy and persistence, from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 20, 2023

Dr Kenric Ware discusses opportunities to increase PrEP awareness and uptake on college campuses in this commentary from Clinical Care Options (CCO)

person default Kenric Ware, PharmD, AAHIVP Released: January 19, 2023

In this case-based video module, Dr Jill Blumenthal shares key data and recommendations about PrEP in transgender young adults, from Clinical Care Options (CCO)

Jill Blumenthal, MD, MAS Released: January 9, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings